Pyrosky/iStock via Getty Images Investment Overview BioNTech SE (NASDAQ:BNTX), the Mainz, Germany-based Pharma company that partnered with Pfizer (PFE) in creating the most successful vaccine of the COVID-19 era, Comirnaty, using a pioneering messenger-RNA (“MRNA”) approach, reported its Q2 2024 earnings yesterday. I last covered BioNTech for Seeking Alpha in June, summarizing its recent fortunes as follows: BioNTech launched its initial public offering ("IPO") back in October 2019, raising $150m at $15 ...